Pharmacokinetics and safety of galantamine in subjects with hepatic impairment and healthy volunteers

Journal of Clinical Pharmacology

Volumn 42, Issue 4, 2002, Pages 428-436

  Zhao, Qinying ^a   Iyer, Ganesh R ^a   Verhaeghe, Tom ^b   Truyen, Luc ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE;

ADULT; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BINDING; DRUG BLOOD LEVEL; DRUG CONCENTRATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; LABORATORY TEST; LIVER DISEASE; LIVER TOXICITY; MALE; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PLASMA CLEARANCE;

EID: 0036207083     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/00912700222011481     Document Type: Article

References (39)

1. The US economic and social costs of Alzheimer's disease revisited
2. First International Pharmacoeconomic Conference on Alzheimer's Disease: Report and summary
3. Consensus statement on the upcoming crisis in geriatric mental health
4. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study
5. Functional disability in Alzheimer's disease
6. Psychiatric symptoms and nursing home placement of patients with Alzheimer's disease
7. Predictive validity of factors influencing the institutionalization of elderly people with psychogeriatric disorders
8. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging
9. The cholinergic hypothesis of geriatric memory dysfunction
10. Alzheimer's disease and senile dementia: Loss of neurons in the basal forebrain
11. Nicotinic cholinoceptive neurons in the frontal cortex are reduced in Alzheimer's disease
12. Alteration in nicotine binding sites in Parkinson's disease, Lewy body dementia and Alzheimer's disease: Possible index of early neuropathology
13. Kinetic analysis of regional (S)(-)11C-nicotine binding in normal and Alzheimer's brains: In vivo assessment using positron emission tomography
14. A 30-week randomised controlled trial of high-dose tacrine in patients with Alzheimer's disease
15. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease
16. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study
17. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: International randomised controlled trial
18. A randomised trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer's disease
19. Long-term tacrine (Cognex) treatment: Effects on nursing home placement and mortality
20. Pharmacological evaluation of novel Alzheimer's disease therapeutics: Acetylcholinesterase inhibitors related to galanthamine
21. Agonist responses of neuronal nicotinic acetylcholine receptors are potentiated by a novel class of allosterically acting ligands
22. Allosteric modulation of nicotinic acetylcholine receptors as a treatment strategy for Alzheimer's disease
23. A 5-month, randomized, placebo-controlled trial of galantamine in AD
24. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension
25. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: Multicentre randomised controlled trial
26. The O-demethylation of the antidementia drug galanthamine is catalysed by cytochrome P450 2D6
27. Value of profiling liver function in the elderly
28. Quantitative liver function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation and caffeine clearance
29. Transection of the esophagus for bleeding esophageal varices
30. Drug pharmacokinetics in cardiac and hepatic disease
31. Pharmacokinetics and metabolism of galanthamine
32. Pharmacokinetics of galanthamine in humans and corresponding cholinesterase inhibition
33. Galantamine: A review of its use in Alzheimer's disease
34. An evaluation of the pharmacokinetics of donepezil HCl in patients with impaired hepatic function
35. Clinical pharmacology of rivastigmine: A new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease
36. The effects of renal and hepatic impairment on the disposition of the acetylcholinesterase inhibitor SDZ ENA 713